Frederick L. Locke, MD

Researchers successfully created a CAR T-cell construct to signal CD58 mutation or loss in patients with large B cell lymphomas, according to a presentation from the ASH Annual Meeting and Exposition.

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition

New data suggest ibrutinib may be able to improve CAR T-cell production when administered before apheresis, according to a presentation at the ASH Annual Meeting and Exposition.

In this installment of In Practice, Frederick L. Locke, MD, Co-Leader of the Immunology Program and Director of the Immune Cell Therapy Program at Moffitt Cancer Center, discusses the side effects and toxicities of CAR T-cell treatments. Though he acknowledges they are common, he emphasizes that they should not hinder the referral of patients who are candidates for these potentially ‘lifesaving treatments.’